Who are ATS907's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fingolimob (FTY), Group S+T, FTY720, Elizaria®, Placebo matching fingolimod, NU100.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ats907.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ATS907 — Competitive Intelligence Brief

ATS907 (ATS907) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P1 receptor antagonist. Area: Autoimmune diseases.

phase 2 S1P1 receptor antagonist S1P1 Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

ATS907 (ATS907) — Altheos, Inc.. ATS907 is a small molecule that targets the S1P1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ATS907 TARGET	ATS907	Altheos, Inc.	phase 2	S1P1 receptor antagonist	S1P1
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Elizaria®	Elizaria®	AO GENERIUM	phase 3	S1P receptor modulator	S1P1
Placebo matching fingolimod	Placebo matching fingolimod	Biogen	phase 3	Sphingosine-1-phosphate receptor modulator	S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors)
NU100	NU100	Nuron Biotech Inc.	phase 3	S1P1 receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P1 receptor antagonist class)

AbbVie · 1 drug in this class
Altheos, Inc. · 1 drug in this class
Jemincare · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATS907 — Competitive Intelligence Brief. https://druglandscape.com/ci/ats907. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab